The 1909 meeting of the Section of Anaesthetics of the Royal Society of Medicine was devoted to the recognition, prevention and treatment of surgical shock, a problem that had attracted greater attention since the introduction of blood pressure measurement. The principal speaker at the meeting, Dudley Buxton, outlined his observations, noting that adequate depth of anaesthesia was required to prevent "psychic shock…irregular nervous explosions causing respiratory and circulatory storms which always make for danger" 2 . But he appreciated that excessively deep anaesthesia could cause or exacerbate hypotension, compounding shock when other surgical variables, such as haemorrhage or visceral traction were present.
Describing the therapies he had been investigating, Buxton noted: "since I have employed oxygen with the anaesthetic, there has been less shock…" 2 . As well as proposing the free and somewhat novel administration of oxygen, Buxton made mention of pharmaceuticals. He dismissed the fashionable injections of ether, alcohol and strychnine, offered some support for digitalis in the failing heart and promoted the new pharmaceutical, adrenaline, which: "if continuously applied, offers much hope" 2 . Continuous application was not easy though; intravenous infusions required surgical insertion of a cannula, were difficult to control and impractical for prolonged periods. Mr Lockhart Mummery, who had also been experimenting with the drug, noted that "clinically adrenalin was useless...it was necessary to keep up the infusion of it into the veins, and watch the pressure by means of a manometer" 2 .
Buxton's work was based almost entirely on the contemporary research of the American surgeon, George Crile. Crile conducted extensive experiments on animals, confirming the efficacy of adrenaline in the treatment of shock and cardiac arrest 3 . He too noted the impracticalities, stressing that some animals died from inadequate dosing and others from too rapid an infusion. He also observed that direct injection of adrenaline into the heart could lead to ventricular fibrillation. Crile's work was so revolutionary it frequently made the local papers; his experiments with decapitated dogs kept alive for hours with adrenaline infusions were reported on the front page of the New York Times 4 . In 1909, after some success with adrenaline in clinical situations, he prepared a protocol for resuscitation, the first to include the administration of adrenaline. Once again, this attracted considerable attention in the press. The publicity prompted a flurry of correspondence, including a letter from a woman who asked if he could resuscitate her husband who had died during an accident some years earlier and was still entombed in a glacier 5, 6 .
Latzko is thought to have been the first to use intracardiac adrenaline in humans. He presented his experiences at a meeting in Vienna in 1909, stating he had been using intracardiac adrenaline with some success for five years 7, 8 . In 1923, Carl Bodon, a US medical officer stationed in Budapest, published a review of the use of intracardiac drugs after successfully resuscitating a man who arrested in the lounge room of their shared boarding house. Bodon used undiluted adrenaline and noted that, while many other drugs such as camphor oil, caffeine, strophanthin and strychnine had been used, "adrenalin has lately, and deservedly, taken the lead in intracardiac injections when there is no time to be lost" 7 . He also observed that the indications listed by the various authors were grouped broadly into three categories of shock: surgical (including anaesthesia), obstetric, and internal diseases. He thought the list unsatisfactory and incomplete, remarking: "So far as I know, nobody has thought of extending the indications to include the very promising and vast field of idiosyncrasies against drugs, and anaphylaxis" 7 .
Anaphylaxis was a relatively newly understood condition, its pathophysiology discovered largely by accident. On July 1905, a steamer sailed from France on a 2½ month voyage of discovery, one of a series of scientific voyages initiated by Prince Albert of Monaco 9 . Among the scientists on board were Paul Portier, a medical doctor from the department of physiology at the University of Paris, and the doctor, author and playwright, Charles Richet, also from Paris. Their mission was to study the Portuguese man-of-war, the long tentacled jellyfish which inflicted extreme pain and disability on its hapless victims. Portier and Richet were hopeful that isolating a toxin would lead to potential treatments. Continuing their work back on shore, they injected animals with repeated low doses of various toxins, hoping to create an immunological treatment. To their surprise, the animals previously exposed to large doses of the toxin died when reinjected with subsequent low doses. Richet's ongoing work in this area led to the understanding of the condition and ultimately, a Nobel Prize. He named the condition 'aphylaxis' (without protection, from the Greek), later changed to anaphylaxis because it was easier to say.
The discovery was well timed. While the condition had been described since ancient times, it was emerging as a more frequent problem due to the development of antitoxins to diphtheria and tetanus. Antitoxins, while saving the lives of many, were also causing isolated deaths. In 1919, T. Harris Boughton reviewed a number of deaths in asthmatics with known allergies to horses 10 . These patients had all died following administration of antitoxins made with horse serum. While Boughton correctly identified the problem as anaphylaxis, there was no mention of treatment. The following year Will Walter reported a near fatal anaphylactic reaction to pollen inoculation noting "it being a wellestablished principle that anaphylatoxic poisoning is best met by increasing blood alkalinity… we adopted an alkaline dietary regimen" 11 .
Bodon was not the first to suggest adrenaline for the treatment of anaphylaxis but in the years following his 1923 publication, there was a marked increase in the use of adrenaline for this condition, by both the intracardiac and intravenous routes. Adrenaline was also discovered to have bronchodilatory properties in 1903 and by the 1920s had widespread application in the treatment of asthma 12, 13 . Given subcutaneously, it was often self-administered by the patient during acute attacks 14 . As the intravenous route became more practical with the development of better equipment, it was realised that intravenous administration was more effective for status asthmaticus 15 . For less severe attacks, the subcutaneous route was eventually supplanted by inhaled adrenaline. James Graeser and Albert Rowe were the first to suggest oral inhalations of adrenaline. Using a 1 in 100 solution, they demonstrated that it was more effective than injections and had less side-effects in many of their patients 14 . As a result, several companies began making special preparations, formulated to work in commercially available atomisers. These solutions were more concentrated than the intravenous preparations raising new safety concerns. The release of Burroughs Wellcome and Co's 1% vaporole prompted an editorial in the British Medical Journal stating: "The bottles of vaporole solution and their containers are labelled "Caution-Not for injection," but we would suggest the advantage of making this warning somewhat more prominent" 16 . Even in these early days of intravenous medication, the potential for errors was all too apparent.
By the 1950s, adrenaline had a well-established place in the treatment of many life-threatening conditions. Despite the development of many other sympathomimetic amines, it remains a crucial part of all resuscitation protocols.
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